Related Experiment Video
Updated: Jun 26, 2025
Laser Doppler: A Tool for Measuring Pancreatic Islet Microvascular Vasomotion In Vivo
Published on: March 8, 2018
Wearable laser Doppler flowmetry for non-invasive assessment of diabetic foot microcirculation: methodological
Xing-Xi Hu1,2, Xiao-Man Xing3,4, Zhen-Ming Zhang1
1Huashan Hospital, Fudan University, Department of Orthopedic Surgery, Shanghai, China.
Significance:
Type 2 diabetes mellitus (T2DM) is a global health concern with significant implications for vascular health. The current evaluation methods cannot achieve effective, portable, and quantitative evaluation of foot microcirculation.
Aim:
We aim to use a wearable device laser Doppler flowmetry (LDF) to evaluate the foot microcirculation of T2DM patients at rest.
Approach:
Eleven T2DM patients and twelve healthy subjects participated in this study. The wearable LDF was used to measure the blood flows (BFs) for regions of the first metatarsal head (M1), fifth metatarsal head (M5), heel, and dorsal foot. Typical wavelet analysis was used to decompose the five individual control mechanisms: endothelial, neurogenic, myogenic, respiratory, and heart components. The mean BF and sample entropy (SE) were calculated, and the differences between diabetic patients and healthy adults and among the four regions were compared.
Results:
Diabetic patients showed significantly reduced mean BF in the neurogenic () and heart () components at the M1 and M5 regions () compared with healthy adults. Diabetic patients had significantly lower SE in the neurogenic () and myogenic () components at the M1 region, as well as in the endothelial () component at the M5 region and in the myogenic component at the dorsal foot (), compared with healthy adults. The SE in the myogenic component at the dorsal foot was lower than at the M5 region () and heel area (). Similarly, the SE in the heart component at the dorsal foot was lower than at the M5 region () and heel area () in diabetic patients.
Conclusions:
This study indicated the potential of using the novel wearable LDF device for tracking vascular complications and implementing targeted interventions in T2DM patients.
